@IOBiotech today announced that the company intends to explore a range of strategic alternatives to maximize stockholder value.
Read the full press release here: bit.ly/3YPUOCS
We are delighted to share that members of our @IOBiotech management team will be heading to San Francisco in just a few short weeks to for partnership and investor meetings on January 12-15.
If you’ll be in San Francisco, we would welcome the opportunity to connect to discuss our lead investigational candidate, Cylembio, and the other candidates in our pipeline of novel off-the-shelf, immune- modulatory therapies with pan-cancer potential. Please reach out if you would like to meet with any of our team members by emailing us at [email protected].
#JPM2026 #CancerImmunotherapy #InvestorConferences
@IOBiotech is pleased to announce the publication in Nature Communications of the long-term clinical and immunological outcomes from MM1636, the Phase 1/2 trial evaluating the investigational peptide vaccine IO102-IO103 targeting both tumor cells and immune-suppressive cells expressing IDO1 and/or PD-L1, in combination with PD-1 blockade in the treatment of first line metastatic melanoma.
Read the full press release with a link to the article here: bit.ly/3MDiJCI
#IOBiotech #CancerImmunotherapy #cancer
@IOBiotech is very pleased to announce that our President and CEO, Mai-Britt Zocca, PhD, will be a Speaker in the Special session with Industry, “How to translate IO research from academia to biotech”, at the ESMO Immuno-Oncology Congress 2025 taking place in London December 10 – 12, 2025.
The Congress is an international event that brings together immune-oncology experts to learn, share research and expertise, and connect with other stakeholders that are making a difference in the immune-oncology field.
Lecture title: IO-Biotech: Ten years journey to change the landscape of cancer vaccines
Date and time: Thursday, December 11, 2025, from – GMT
Learn more about the full program here: bit.ly/445Yof1
#IOBiotech #CancerImmunotherapy
@IOBiotech is pleased to announce that members of its executive management team will be attending the following upcoming December investor conferences:
Event: 8th Annual Evercore Healthcare Conference
Location: Coral Gables, Florida
Fireside chat: Tuesday, December 2, 2025, at 7:55 am ET
Participants: Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO
Event: Piper Sandler 36th Annual Healthcare Conference
Location: New York, New York
Fireside chat: Wednesday, December 3, 2025, at 3:00 pm ET
Participants: Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO
See the full press release for more details and webcast links: bit.ly/4rlbcYL
#IOBiotech #cancer #InvestorConferences
@IOBiotech today reported financial results for the third quarter of 2025. Read more here: bit.ly/4oJnclo
#IOBiotech #cancervaccines #financialresults
@IOBiotech is pleased to announce that members of its executive management team will be attending the following upcoming investor conferences:
Event: Jefferies Global Healthcare Conference
Format: Company presentation
Date: Tuesday, November 18, 2025, 3:00 PM GMT
Presenter: Mai-Britt Zocca, PhD, President & CEO
Event: Piper Sandler 36th Annual Healthcare Conference
Format: Fireside chat
Date: Wednesday, December 3, 2025, 3:00 PM ET
Participants: Mai-Britt Zocca, PhD, President & CEO and Amy Sullivan, CFO
See the full press release for more details: bit.ly/4oBy18V
#IOBiotech #cancer #InvestorConferences
We are pleased to have Inés Lecoq Molinos, PhD, Senior Scientist, at the SITC Annual Meeting today to present preclinical findings on the potential of our novel investigational immune-modulatory vaccine, IO170 targeting TGF-β, to potentially enhance the treatment efficacy for a wide range of cancers.
To learn more, visit the poster presentation today, November 8th from 12:15 – 1:45 PM ET in Exhibit Halls AB.
@IOBiotech today announced new pre-clinical data for its next vaccine candidate IO112 targeting arginase 1 and additional candidate IO170 targeting TGF-β, will be presented at the SITC Annual Meeting taking place in Maryland on November 5-9, 2025.
Read the full press release here: bit.ly/4qLVKov
Our @IOBiotech team is proud to support Lung Cancer Awareness Month this November! Lung cancer is the leading cause of cancer deaths in the United States and globally, and it is important to encourage those at risk to take proactive steps towards prevention, detention, and early treatment. At #IOBiotech, we are dedicated to advancing research to enhance treatment options for people with multiple types of cancer, including lung cancer.
For more information about our ongoing efforts and our T-win® technology platform, please visit our website: iobiotech.com
